{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:52:23Z","timestamp":1761058343849},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Nuerosci"],"published-print":{"date-parts":[[1996,8]]},"DOI":"10.1007\/bf02190273","type":"journal-article","created":{"date-parts":[[2005,9,21]],"date-time":"2005-09-21T03:23:54Z","timestamp":1127273034000},"page":"229-234","source":"Crossref","is-referenced-by-count":22,"title":["Review: Treatment of schizophrenia"],"prefix":"10.1007","volume":"246","author":[{"given":"H. -J.","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02190273_CR1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/archpsyc.1988.01800250095013","volume":"45","author":"RJ Baldessarini","year":"1988","unstructured":"Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR2","volume-title":"Pharamkotherapie in der Psychiatrie","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Fleischhacker WW, Sperk G (1991) Pharamkotherapie in der Psychiatrie. Thieme, Stuttgart"},{"key":"BF02190273_CR3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","volume":"10","author":"TR Barnes","year":"1994","unstructured":"Barnes TR, Curson DA (1994) Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 10:464\u2013479","journal-title":"Drug Saf"},{"key":"BF02190273_CR4","volume-title":"Psychiatrische Pharmakotherapie","author":"O Benkert","year":"1996","unstructured":"Benkert O, Hippius H (1996) Psychiatrische Pharmakotherapie. 6. ed. Springer-Verlag, Berlin Heidelberg New York","edition":"6. ed."},{"key":"BF02190273_CR5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00004714-199102000-00004","volume":"11","author":"I Bitter","year":"1991","unstructured":"Bitter I, Volavka J, Scheurer J (1991) The concept of the neuroleptic threshold: an update. J Clin Psychopharmacol 11:28\u201333","journal-title":"J Clin Psychopharmacol"},{"key":"BF02190273_CR6","first-page":"72","volume":"58","author":"HD Brenner","year":"1987","unstructured":"Brenner HD, Hodel B, Kube G, Roder V (1987) Kognitive Therapie bei Schizophrenen: Problemanalyse und empirische Ergebnisse. Nervenarzt 58:72\u201383","journal-title":"Nervenarzt"},{"key":"BF02190273_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0767-399X(96)80071-X","volume":"10","author":"G Buchkremer","year":"1995","unstructured":"Buchkremer G, Schulze M\u00f6nking H, Holle R, Hornung WP (1995) The impact of therapeutic relatives' groups on the course of illness of schizophrenic patients. Eur Psychiatry 10:17\u201327","journal-title":"Eur Psychiatry"},{"key":"BF02190273_CR8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/schbul\/11.3.440","volume":"11","author":"WT Carpenter","year":"1985","unstructured":"Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:440\u2013452","journal-title":"Schizophr Bull"},{"key":"BF02190273_CR9","first-page":"21","volume":"18","author":"WT Carpenter","year":"1992","unstructured":"Carpenter WT, Stevens JH, Rey AC (1992) Early intervention vs. continuous pharmacotherapy in schizophrenia. Psychopharmacol Bull 18:21\u201323","journal-title":"Psychopharmacol Bull"},{"key":"BF02190273_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","volume":"11","author":"SG Dahl","year":"1986","unstructured":"Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokin 11:36\u201361","journal-title":"Clin Pharmacokin"},{"key":"BF02190273_CR11","unstructured":"Deister A, M\u00f6ller HJ, Schizophrenie. Springer (in press)"},{"key":"BF02190273_CR12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1176\/ajp.149.11.1549","volume":"149","author":"TA Eckman","year":"1992","unstructured":"Eckman TA, Wirshing WC, Marder SR, Liberman RP, Johnston Cronk K, Zimmerman K, Mintz J (1992) Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 149:1549\u20131555","journal-title":"Am J Psychiatry"},{"issue":"Suppl 382","key":"BF02190273_CR13","first-page":"11","volume":"89","author":"WW Fleischhacker","year":"1994","unstructured":"Fleischhacker WW, Meise U, Gunther V, Kurtz M (1994) Compliance with antipsychotic treatment, influence of side-effects. Acta Psychiatr Scand 89, Suppl 382:11\u201315","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl. 21","key":"BF02190273_CR14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/S0007125000292416","volume":"163","author":"W Gaebel","year":"1993","unstructured":"Gaebel W, Frick U, K\u00f6pcke W, Linden M, M\u00fcller P, M\u00fcller-Spahn F, Pietzcker A, Tegeles J (1993) Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 163 (Suppl. 21):8\u201312","journal-title":"Br J Psychiatry"},{"key":"BF02190273_CR15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00005053-197411000-00004","volume":"159","author":"G Gardos","year":"1974","unstructured":"Gardos G (1974) Are antipsychotic drugs interchangeable? J Nerv Ment Dis 159:343\u2013348","journal-title":"J Nerv Ment Dis"},{"key":"BF02190273_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/schbul\/10.1.30","volume":"10","author":"PJ Goodnick","year":"1984","unstructured":"Goodnick PJ, Meltzer HY (1984) Treatment of schizoaffective disorders. Schizophr Bull 10:30\u201348","journal-title":"Schizophr Bull"},{"key":"BF02190273_CR17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archpsyc.1991.01810280049007","volume":"48","author":"MI Herz","year":"1991","unstructured":"Herz MI, Glazer WM, Mostert MA (1991) Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 48:333\u2013339","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR18","first-page":"102","volume-title":"Neuroleptika. Neuro-Psychopharmaka. 4","author":"H Hinterhuber","year":"1992","unstructured":"Hinterhuber H, Haring C (1992) Unerw\u00fcnschte Wirkungen, Kontraindikationen, \u00dcberdosierungen, Intoxikation. In: Riederer P, Laux G, P\u00f6ldinger W (eds) Neuroleptika. Neuro-Psychopharmaka. 4. Springer, Wien, pp 102\u201321"},{"key":"BF02190273_CR19","volume-title":"Schizophrenia","author":"SR Hirsch","year":"1995","unstructured":"Hirsch SR, Weinberger DR (1995) Schizophrenia. Blackwell Science, Oxford"},{"key":"BF02190273_CR20","volume-title":"Psychosocial treatment of schizophrenia. 72","author":"SR Hirsch","year":"1987","unstructured":"Hirsch SR, Jolley AG, Manchanda R, McRink A (1987) Early intervention medication as an alternative to continuous depot treatment in schizophrenia: Preliminary report. In: Strauss J, Boker W, Brenner HD (eds) Psychosocial treatment of schizophrenia. 72. Huber, Bern,-63"},{"key":"BF02190273_CR21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/archpsyc.1979.01780120013001","volume":"36","author":"GE Hogarty","year":"1979","unstructured":"Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36:1283\u20131294","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.1986.01800070019003","volume":"43","author":"GE Hogarty","year":"1986","unstructured":"Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ (1986) Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 43:633\u2013642","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1192\/bjp.126.5.457","volume":"126","author":"DAW Johnson","year":"1975","unstructured":"Johnson DAW (1975) Observations on the dose regimens of fluphenazine decanoate in maintenance therapy of schizophrenia. Br J Psychiatry 126:457\u2013461","journal-title":"Br J Psychiatry"},{"key":"BF02190273_CR24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/19.2.287","volume":"19","author":"JM Kane","year":"1993","unstructured":"Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287\u2013302","journal-title":"Schizophr Bull"},{"key":"BF02190273_CR25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","volume":"40","author":"JM Kane","year":"1983","unstructured":"Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos Lorenzi J (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40:893\u2013896","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR26","first-page":"254","volume":"22","author":"JM Kane","year":"1986","unstructured":"Kane JM, Woerner M, Borenstein M, Wegner J, Liebermann J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254\u2013258","journal-title":"Psychopharmacol Bull"},{"key":"BF02190273_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Sawyer J, Meltzer HY (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chloropromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR28","unstructured":"Kane J, M\u00f6ller H-J, Awouters F, Serotonergic mechanism in antipsychotic treatment. Marcel Dekker, New York (in press)"},{"key":"BF02190273_CR29","first-page":"309","volume":"29","author":"BJ Kinon","year":"1993","unstructured":"Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29:309\u2013314","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 382","key":"BF02190273_CR30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0447.1994.tb05860.x","volume":"89","author":"W Kissling","year":"1994","unstructured":"Kissling W (1994) Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 89 (Suppl 382):16\u201324","journal-title":"Acta Psychiatr Scand"},{"key":"BF02190273_CR31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1176\/ajp.143.4.523","volume":"143","author":"RP Liberman","year":"1986","unstructured":"Liberman RP, Massell HK, Wallace CJ (1986) Social skills training for schizophrenic individuals at risk for relapse. Am J Psychiatry 143:523\u2013526","journal-title":"Am J Psychiatry"},{"key":"BF02190273_CR32","first-page":"605","volume-title":"Schizophrenia","author":"RP Liberman","year":"1995","unstructured":"Liberman RP, Spauling WD, Corrigan PW (1995) Cognitive-behavioural therapies in psychiatric rehabilitation. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 605\u2013625"},{"key":"BF02190273_CR33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","volume":"50","author":"J Lieberman","year":"1993","unstructured":"Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M (1993) Time course and biological correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 50:369\u2013376","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archpsyc.1987.01800180028005","volume":"44","author":"SR Marder","year":"1987","unstructured":"Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR (1987) Low- and conventional-dose maintenance therapy with fluphenazine. Two-year outcome. Arch Gen Psychiatry 44: 518\u2013521","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","volume":"48","author":"JP McEvoy","year":"1991","unstructured":"McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Psychiatry 48:739\u2013745","journal-title":"Arch Psychiatry"},{"key":"BF02190273_CR36","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archpsyc.1989.01810070098017","volume":"46","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY (1989) Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 46:672","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","volume":"18","author":"HY Meltzer","year":"1992","unstructured":"Meltzer HY (1992) Treatment of the neuroleptic non-responsive schizophrenic patient. Schizophr Bull 18:515\u2013542","journal-title":"Schizophr Bull"},{"key":"BF02190273_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-642-93466-7_6","volume-title":"Leitlinien neuroleptischer Therapie","author":"HM M\u00f6ller","year":"1990","unstructured":"M\u00f6ller HM (1990) Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K (ed) Leitlinien neuroleptischer Therapie. Springer, Berlin Heidelberg New York, pp 97\u2013115"},{"key":"BF02190273_CR39","first-page":"153","volume-title":"Neuro-Psychopharmaka. 4","author":"HJ M\u00f6ller","year":"1992","unstructured":"M\u00f6ller HJ (1992) Neuroleptische Rezidivprophylaxe und Langzeitbehandlung schizophrener Psychosen. In: Riederer P, Laux G, P\u00f6ldinger W (eds) Neuro-Psychopharmaka. 4. Springer. Wien, pp 153\u201368"},{"key":"BF02190273_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-977X(93)90289-X","volume":"3","author":"HJ M\u00f6ller","year":"1993","unstructured":"M\u00f6ller HJ (1993a) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3:1\u201311","journal-title":"Eur Neuropsychopharmacol"},{"key":"BF02190273_CR41","first-page":"200","volume-title":"Therapie psychiatrischer Erkrankungen","author":"HJ M\u00f6ller","year":"1993","unstructured":"M\u00f6ller HJ (1993b) Medikament\u00f6se Rezidivprophylaxe schizophrener Erkrankungen. In: M\u00f6ller HJ (ed) Therapie psychiatrischer Erkrankungen. Enke, Stuttgart, pp 200\u201311"},{"key":"BF02190273_CR42","first-page":"142","volume-title":"Critical issues in the treatment of schizophrenia. Int Acad Biomed Drug Res, Vol. 10","author":"H-J M\u00f6ller","year":"1995","unstructured":"M\u00f6ller H-J (1995) Extrapyramidal side effects of neuroleptic medication: focus on risperidone. In: Brunello N, Raccagni G, Langer SZ, Mendlewicz J (eds) Critical issues in the treatment of schizophrenia. Int Acad Biomed Drug Res, Vol. 10. Karger, Basel, pp 142\u2013151"},{"key":"BF02190273_CR43","first-page":"159","volume-title":"Schizoaffective Psychosen. Diagnose, Therapie und Prophylaxe","author":"HJ M\u00f6ller","year":"1989","unstructured":"M\u00f6ller HJ, Morin C (1989) Behandlung schizodepressiver Syndrome mit Antidepressiva. In: Marneros A (ed) Schizoaffective Psychosen. Diagnose, Therapie und Prophylaxe. Springer, Berlin Heidelberg New York pp, 159\u201378"},{"key":"BF02190273_CR44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/978-3-642-61076-9_14","volume-title":"Implications of psychopharmacology to psychiatry. Biological, nosological, and therapeutical concepts","author":"H-J M\u00f6ller","year":"1996","unstructured":"M\u00f6ller H-J, Rao ML (1996) Negative symptoms of schizophrenia: Methodological issues, biochemical findings and efficacy of neuroleptic treatment. In: Ackenheil M, Bondy B, Engel R, Ermann M, Nedopil N (eds) Implications of psychopharmacology to psychiatry. Biological, nosological, and therapeutical concepts. Springer, Berlin Heidelberg New York, pp 158\u201378"},{"key":"BF02190273_CR45","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-71021-6","volume-title":"Der Verlauf schizophrener Psychosen unter den gegenw\u00e4rtigen Behandlungsbedingungen","author":"HJ M\u00f6ller","year":"1986","unstructured":"M\u00f6ller HJ, von Zerssen D (1986) Der Verlauf schizophrener Psychosen unter den gegenw\u00e4rtigen Behandlungsbedingungen. Springer, Berlin Heidelberg New York"},{"key":"BF02190273_CR46","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.139.12.1571","volume":"139","author":"HJ M\u00f6ller","year":"1982","unstructured":"M\u00f6ller HJ, Kissling W, Lang C, Doerr P, Pirke KM, Von Zerssen D (1982) Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 139:1571\u20131575","journal-title":"Am J Psychiatry"},{"key":"BF02190273_CR47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","volume":"245","author":"HJ M\u00f6ller","year":"1995","unstructured":"M\u00f6ller HJ, M\u00fcller H, Borison RL, Schooler NR, Chouinard G (1995) A pathanalytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenia patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45\u201349","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"BF02190273_CR48","first-page":"626","volume-title":"Schizophrenia","author":"KT Mueser","year":"1995","unstructured":"Mueser KT, Bellack AS (1995) Psychotherapy for schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 626\u201348"},{"key":"BF02190273_CR49","first-page":"649","volume-title":"Schizophrenia","author":"M Muijen","year":"1995","unstructured":"Muijen M, Hadley T (1995) Community care: parts and systems. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 649\u201363"},{"key":"BF02190273_CR50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","volume":"33","author":"A-L Nordstrom","year":"1993","unstructured":"Nordstrom A-L, Farde L, Wiesel FA (1993) Central D \u2014 dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227\u2013235","journal-title":"Biol Psychiatry"},{"key":"BF02190273_CR51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archpsyc.1979.01780050079010","volume":"36","author":"BA Prusoff","year":"1979","unstructured":"Prusoff BA, Williams DH, Weissman MM, Astrachan BA (1979) Treatment of secondary depression in schizophrenia. Arch Gen Psychiat 36:569\u2013575","journal-title":"Arch Gen Psychiat"},{"key":"BF02190273_CR52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1176\/ajp.146.6.726","volume":"146","author":"GT Reardon","year":"1989","unstructured":"Reardon GT, Rifkin A, Schwartz A, Myerson A, Siris SH (1989) Changing pattern of neuroleptic dosage over time. Am J Psychiatry 146:726\u2013729","journal-title":"Am J Psychiatry"},{"key":"BF02190273_CR53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/archpsyc.1991.01810260074011","volume":"48","author":"A Rifkin","year":"1991","unstructured":"Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachpress M (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48:166\u2013170","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR54","first-page":"167","volume":"9","author":"M Sagatovic","year":"1993","unstructured":"Sagatovic M, Meltzer HY (1993) The effect of short-term electroconvulsive treatment plus neuroleptic in treatment-resistant schizophrenia and schizoaffective disorder. Convulsive Therapy 9:167\u2013175","journal-title":"Convulsive Therapy"},{"key":"BF02190273_CR55","first-page":"111","volume-title":"The neuroleptic-nonresponsive patient: Characterization and treatment","author":"SC Schulz","year":"1990","unstructured":"Schulz SC, Kahn EM, Baker RW, Conley RR (1990) Lithium and Carbamazepine. Augmentation in treatment-refractory schizophrenia. In: Angrist B, Schulz SC (eds) The neuroleptic-nonresponsive patient: Characterization and treatment. American Psychiatric Press, Inc. Washington, London, pp 111\u201336"},{"key":"BF02190273_CR56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0447.1993.tb03335.x","volume":"87","author":"A Shalev","year":"1993","unstructured":"Shalev A, Hermesh H, Rothberg J, Munitz H (1993) Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 87:86\u201391","journal-title":"Acta Psychiatr Scand"},{"key":"BF02190273_CR57","first-page":"128","volume-title":"Schizophrenia","author":"SG Siris","year":"1995","unstructured":"Siris SG (1995) Depression and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell Science, Oxford, pp 128\u201345"},{"key":"BF02190273_CR58","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1978.01770350094009","volume":"35","author":"SG Siris","year":"1978","unstructured":"Siris SG, Kammen vDP, Docherty JP (1978) Use of antidepressant drugs in schizophrenia. Arch Gen Psychiatry 35:1368\u20131377","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archpsyc.1990.01810200062009","volume":"47","author":"T Putten Van","year":"1990","unstructured":"Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47:754\u2013758","journal-title":"Arch Gen Psychiatry"},{"key":"BF02190273_CR60","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/schbul\/8.2.425","volume":"8","author":"CE Vaughn","year":"1982","unstructured":"Vaughn CE, Snyder KS, Freeman W, Jones S, Falloon IR, Liberman RP (1982) Family factors in schizophrenia relapse: a replication. Schizophr Bull 8:425\u2013426","journal-title":"Schizophr Bull"},{"key":"BF02190273_CR61","volume-title":"Therapie, Rehabilitation und Pr\u00e4vention schizophrener Erkrankungen","author":"JK Wing","year":"1976","unstructured":"Wing JK (1976) Eine praktische Grundlage f\u00fcr die Soziotherapie bei Schizophrenie. In: Huber G (ed) Therapie, Rehabilitation und Pr\u00e4vention schizophrener Erkrankungen. Schattauer, Stuttgart, New York"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02190273\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02190273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T13:33:35Z","timestamp":1557840815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02190273"}},"subtitle":["State of the art"],"short-title":[],"issued":{"date-parts":[[1996,8]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1996,8]]}},"alternative-id":["BF02190273"],"URL":"https:\/\/doi.org\/10.1007\/bf02190273","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,8]]}}}